Patents by Inventor Herbert Rudolf Treutlein
Herbert Rudolf Treutlein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8329737Abstract: A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, C1-4 alkyl, O, S, SO2, CO or CS and X1, X2, X3 and X4 are optionally substituted by 9 specific substituents or one can be nitrogen. Compositions comprising a carrier and at least one compound of formula (I) are also provided. Further provided are methods of treating tyrosine kinase-associated disease states by administering a compound of formula (I) and methods of suppressing the immune system of a subject by administering a compound of formula (I).Type: GrantFiled: September 30, 2010Date of Patent: December 11, 2012Assignee: YM Biosciences Australia PTY LtdInventors: Michelle Leanne Styles, Jun Zeng, Herbert Rudolf Treutlein, Andrew Frederick Wilks, Marcel Robert Kling, Xianyong Bu, Christopher John Burns
-
Publication number: 20110082142Abstract: A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, C1-4 alkyl, O, S, SO2, CO or CS and X1, X2, X3 and X4 are optionally substituted by 9 specific substituents or one can be nitrogen. Compositions comprising a carrier and at least one compound of formula (I) are also provided. Further provided are methods of treating tyrosine kinase-associated disease states by administering a compound of formula (I) and methods of suppressing the immune system of a subject by administering a compound of formula (I).Type: ApplicationFiled: September 30, 2010Publication date: April 7, 2011Inventors: MICHELLE LEANNE STYLES, JUN ZENG, HERBERT RUDOLF TREUTLEIN, ANDREW FREDERICK WILKS, MARCEL ROBERT KLING, XIANYONG BU, CHRISTOPHER JOHN BURNS
-
Publication number: 20090269355Abstract: The present invention relates generally to a growth factor precursor and its use to select production of antigen specific catalytic antibodies. Such catalytic antibodies are produced following B cell activation and proliferation induced by catalytic cleavage products of a target antigen portion of the growth factor precursor of the present invention. A particularly useful form of the growth factor precursor is as a nucleic acid vaccine. The nucleic acid vaccine of the present invention preferably further comprises a molecular adjuvant. Another aspect of the present invention comprises a growth factor precursor in multimeric form. The growth factor precursor of the present invention is useful for generating catalytic antibodies for both therapeutic, diagnostic and industrial purposes.Type: ApplicationFiled: October 31, 2007Publication date: October 29, 2009Inventors: Frank Koentgen, Gabriele Maria Suess, David Mathew Tarlinton, Herbert Rudolf Treutlein
-
Publication number: 20080207613Abstract: A compound of the general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof, wherein A represents a variety of six membered nitrogen containing heterocyclic rings, Q is a bond, halogen, C1-4 alkyl, O, S, SO2, CO or CS and X1, X2, X3 and X4 are optionally substituted by 9 specific substituents or one can be nitrogen. Compositions comprising a carrier and at least one compound of formula (I) are also provided. Further provided are methods of treating tyrosine kinase-associated disease states by administering a compound of formula (I) and methods of suppressing the immune system of a subject by administering a compound of formula (I).Type: ApplicationFiled: January 12, 2005Publication date: August 28, 2008Applicant: CYTOPIA RESEARCH PTY LTDInventors: Michelle Leanne Styles, Jun Zeng, Herbert Rudolf Treutlein, Andrew Frederick Wilks, Marcel Robert Kling, Christopher John Burns, Xianyong Bu
-
Patent number: 6941229Abstract: The present invention relates to a method of designing compounds able to bind to a molecule of the EGF receptor family and to modulate the activity mediated by the receptor molecule based on the 3-D structure coordinates of the EGF receptor crystal of FIG. 6.Type: GrantFiled: May 31, 1999Date of Patent: September 6, 2005Assignees: Commonwealth Scientific and Industrial Research Organization, Ludwig Institute for Cancer ResearchInventors: Thomas Charles Elleman, Vidanagamage Chandana Epa, Thomas Peter John Garrett, Robert Nicholas Jorissen, Meizhen Lou, Antony Wilks Burgess, Neil Moreton McKern, Herbert Rudolf Treutlein, Colin Lesley Ward
-
Publication number: 20030148484Abstract: The present invention relates generally to a growth factor precursor and its use to select production of antigen specific catalytic antibodies. Such catalytic antibodies are produced following B cell activation and proliferation induced by catalytic cleavage products of a target antigen portion of the growth factor precursor of the present invention. A particularly useful form of the growth factor precursor is as a nucleic acid vaccine. The nucleic acid vaccine of the present invention preferably further comprises a molecular adjuvant. Another aspect of the present invention comprises a growth factor precursor in multimeric form. The growth factor precursor of the present invention is useful for generating catalytic antibodies for both therapeutic, diagnostic and industrial purposes.Type: ApplicationFiled: January 16, 2003Publication date: August 7, 2003Inventors: Frank Koentgen, Gabriele Maria Suess, David Mathew Tarlinton, Herbert Rudolf Treutlein
-
Patent number: 6590080Abstract: The present invention relates generally to a growth factor precursor and its use to select production of antigen specific catalytic antibodies. Such catalytic antibodies are produced following B cell activation and proliferation induced by catalytic cleavage products of a target antigen portion of the growth factor precursor of the present invention. A particularly useful form of the growth factor precursor is as a nucleic acid vaccine. The nucleic acid vaccine of the present invention preferably further comprises a molecular adjuvant. Another aspect of the present invention comprises a growth factor precursor in multimeric form. The growth factor precursor of the present invention is useful for generating catalytic antibodies for both therapeutic, diagnostic and industrial purposes.Type: GrantFiled: June 9, 2000Date of Patent: July 8, 2003Inventors: Frank Koentgen, Gabriele Maria Suess, David Mathew Tarlinton, Herbert Rudolf Treutlein
-
Patent number: 6521741Abstract: The present invention is directed generally to catalytic antibodies and, more particularly, to a novel method of producing same. The method of the present invention is predicated in part on the exploitation of the products of catalysis to induce B cell mitogenesis. In a preferred embodiment, a growth factor having an ability to induce B cell mitogenesis is linked to a target antigen to which catalytic antibodies are sought. B cell mitogenesis is then dependent on the catalytic cleavage of the antigen portion of the growth factor by catalytic antibodies on the surface of B cells. The method of the present invention is useful for generating catalytic antibodies for both therapeutic and diagnostic purposes.Type: GrantFiled: November 9, 2000Date of Patent: February 18, 2003Assignee: Frank Koentgen Pty Ltd.Inventors: Frank Koentgen, Gabriele Maria Suess, David Mathew Tarlinton, Herbert Rudolf Treutlein
-
Patent number: 6326179Abstract: The present invention is directed generally to catalytic antibodies and, more particularly, to a novel method of producing same. The method of the present invention is predicated in part on the exploitation of the products of catalysis to induce B cell mitogenesis. In a preferred embodiment, a growth factor having an ability to induce B cell mitogenesis is linked to a target antigen to which catalytic antibodies are sought. B cell mitogenesis is then dependent on the catalytic cleavage of the antigen portion of the growth factor by catalytic antibodies on the surface of B cells. The method of the present invention is useful for generating catalytic antibodies for both therapeutic and diagnostic purposes.Type: GrantFiled: September 25, 1998Date of Patent: December 4, 2001Inventors: Frank Koentgen, Gabriele Maria Suess, David Mathew Tarlinton, Herbert Rudolf Treutlein
-
Patent number: 6043069Abstract: The present invention is directed generally to catalytic antibodies and, more particularly, to a novel method of producing same. The method of the present invention is predicated in part on the exploitation of the products of catalysis to induce B cell mitogenesis. In a preferred embodiment, a growth factor having an ability to induce B cell mitogenesis is linked to a target antigen to which catalytic antibodies are sought. B cell mitogenesis is then dependent on the catalytic cleavage of the antigen portion of the growth factor by catalytic antibodies on the surface of B cells. The method of the present invention is useful for generating catalytic antibodies for both therapeutic and diagnostic purposes.Type: GrantFiled: March 26, 1997Date of Patent: March 28, 2000Assignee: Amrad Operations Pty. Ltd.Inventors: Frank Koentgen, Gabriele Maria Suess, David Mathew Tarlinton, Herbert Rudolf Treutlein